Vyome Holdings expands cash reserves to $8.8M as FDA dialogues advance
Vyome Holdings (NASDAQ:HIND) reported an expanded cash runway for the first quarter of 2026, leveraging a recent equity injection to fund regulatory steps and clinical trial preparations for its immuno-inflammatory and rare disease pipeline.










